Revenue segments as reported by the company.

Sensor and other revenue

Hardware revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Collaborative research and development fee

Selling, general and administrative

Amortization of intangible assets

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

DexCom

DexCom, Inc. is a medical device manufacturing company, which engages in the design, development and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G6 CGM System, DexCom G6 CGM System for Medicare, Software and Mobile apps. The company was founded by John F. Burd on May 1, 1999 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

DexCom excels in Q4 2022, eyes international expansion and margin growth

DexCom's Q4 2022 showcased robust financials, operational efficiency, and strategic advancements. The company is well-positioned for continued growth in 2023, with a focus on international expansion, marketing investments, and margin optimization.

DexCom excels in Q1, eyes international growth and market expansion

DexCom's strong Q1 performance and strategic initiatives position the company for sustained growth.
Balancing cost management, market expansion, and product enhancements will be crucial for future success.
Opportunities in new markets, user segments, and product improvements offer avenues for continued growth.
Overall, DexCom's focus on innovation and customer-centric strategies bode well for its long-term prospects.

DexCom reports robust Q2 earnings, eyes international expansion and new products

DexCom's Q2 performance reflects strong revenue growth and market momentum, supported by successful product launches and international expansion.
The company's focus on innovation, customer satisfaction, and cost reduction initiatives positions it well for continued success and market leadership.
While facing challenges in customer experience and product adoption, DexCom's strategic strengths and growth opportunities signal a promising outlook for the future.

DexCom achieves record Q3 performance and expands market leadership

DexCom's Q3 performance reflects strong revenue growth, operational efficiency, and strategic market expansion efforts, setting new records in financial metrics.
The company's strengths lie in market leadership, product innovation, and proactive market expansion strategies, supported by a strong brand and organizational culture.
While facing challenges in pricing strategies, timeline for revenue contributions, and distribution accessibility, DexCom is well-positioned to capitalize on opportunities in new markets and product launches.
Overall, DexCom's performance, strengths, and proactive approach to challenges and opportunities position it for sustained growth and market leadership in the medical devices sector.

DexCom excels in Q4 2023, eyes growth through strategic initiatives

DexCom's strong financial performance, product launches, and market expansions in 2023 set a solid foundation for future growth.
Strategic investments, competitive advantages, and a focus on margin progression position DexCom for continued success.
Challenges in reimbursement pathways and market penetration are being addressed, while opportunities in expanding coverage and product enhancements are being pursued.

DexCom excels in Q1 2024, eyes global expansion and innovation

DexCom's strong financial performance, strategic market expansions, and product innovations position the company for continued growth and success.
While facing challenges in market penetration and product adoption timelines, DexCom's focus on user experience and healthcare outcomes remains a key strength.
Opportunities lie in international market expansion, product differentiation, and leveraging sensor technology for improved patient care and business growth.

DexCom reports 15% revenue growth but lowers full-year guidance

DexCom faced challenges in customer additions and revenue per customer in the U.S. and below-expectation international performance. Despite this, they reported 15% revenue growth and lowered full-year revenue guidance to 11%-13% organic growth.

DexCom meets revenue targets, Stelo launch successful, challenges ahead

DexCom's Q3 performance met expectations with growth in key areas.
Strong market reception for Stelo presents revenue and growth opportunities.
Challenges exist in managing differing customer expectations and sensor performance.
Opportunities lie in expanding international markets and enhancing customer experiences.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

DexCom, Inc. is a medical device company, which engages in the design, development, and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G6, Dexcom G7, Dexcom Stelo, Dexcom Share, Dexcom Real-Time API, and Dexcom ONE. The company was founded by John F. Burd on May 13, 1999 and is headquartered in San Diego, CA.

Abbott Labs

These two companies are battling for market share of continuous glucose monitoring devices for diabetes, with each coming out with new models soon.

Better Buy: Abbott Laboratories vs. DexCom

G7 could change the valuation dramatically. It is a risky play, especially in the short term.

DexCom: The End Of The Beginning Is Almost Here

Exact Sciences

Instead of investing in the company that would have made you a millionaire years ago, seek out the ones that have the potential from here.

Forget Apple! Buy These 2 High-Growth Stocks Instead

Becton, Dickinson and Co.

Teladoc

UnitedHealth Group

Vertex Pharmaceuticals

These stocks have beaten the odds in 2020 and can weather future storms.

5 Top Healthcare Stocks to Buy in November

Alarm.com

Cisco Systems

Intel

NVIDIA

NXP Semiconductors

With the disruption that the coronavirus caused us, the dependency on tech-based solutions makes these IoT stocks very relevant. The post 7 IoT Stocks That Are Banking on a Connected Future appeared first on InvestorPlace.

7 IoT Stocks That Are Banking on a Connected Future

An analyst downgrade and marketwide turbulence weighed on the medical device maker's shares last month.

Why DexCom Stock Crumbled in October

This medical device manufacturer has shown incredible momentum.

Why Is No One Talking About DexCom Stock?

A Relative Strength Rating upgrade for Dexcom shows improving technical performance. The post Stock Upgrades: Dexcom Shows Rising Relative Strength appeared first on Investor's Business Daily.

Stock Upgrades: Dexcom Shows Rising Relative Strength

Amazon

Alphabet

Honeywell

Johnson Controls

IOT stocks represent companies on the cusp of a new paradigm where everyday objects connect to the internet. Here are seven that stand out.

7 IOT Stocks to Buy As the World Embraces a Hyper-Connected Future

Gilead Sciences

iShares Nasdaq Biotechnology ETF

IDEXX Laboratories

Moderna

Pfizer

QuidelOrtho Corp

If you're interested in high-growth biotech stocks with superior fundamentals, here are which ones to consider, and which ones to skip. The post Which Biotech Stocks Are a Buy on Earnings?

Which Biotech Stocks Are a Buy on Earnings?

SAN DIEGO--(BUSINESS WIRE)--Dexcom to Host Investor Day on December 9, 2020

Dexcom to Host Investor Day on December 9, 2020

The diabetes care technology provider also again raised its full-year guidance.

How DexCom Trounced Wall Street Estimates in Q3

DexCom, Inc. (DXCM) CEO Kevin Sayer on Q3 2020 Results - Earnings Call Transcript

DexCom (DXCM) delivered earnings and revenue surprises of 46.88% and 4.96%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

DexCom (DXCM) Q3 Earnings and Revenues Top Estimates

SAN DIEGO--(BUSINESS WIRE)--Dexcom Reports Third Quarter 2020 Financial Results

Dexcom Reports Third Quarter 2020 Financial Results

SAN DIEGO--(BUSINESS WIRE)--Dexcom Announces Retirement of Rick Doubleday and Pre-Announcement of Third Quarter 2020 Revenue

Dexcom Announces Retirement of Rick Doubleday and Pre-Announcement of Third Quarter 2020 Revenue

Inari Medical

These fast-growing medical device companies could outperform the S&P 500 over the next several years.

Why I Just Bought These 2 Under-the-Radar Stocks

DexCom (DXCM) closed at $387.84 in the latest trading session, marking a -1.17% move from the prior day.

DexCom (DXCM) Dips More Than Broader Markets: What You Should Know

DexCom's (DXCM) third-quarter results are likely to reflect rising global awareness of its real-time CGM.

DexCom (DXCM) to Report Q3 Earnings: What's in the Cards?

These two healthcare companies have much more room to grow than the tech giant does.

2 Unstoppable Stocks That Are Better Buys Than Apple

SAN DIEGO--(BUSINESS WIRE)--Dexcom Appoints Kyle Malady to Board of Directors

Dexcom Appoints Kyle Malady to Board of Directors

Eli Lilly

INDIANAPOLIS and SAN DIEGO, Oct. 7, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and DexCom, Inc. (NASDAQ: DXCM) announced today a joint program for U.S. healthcare providers (HCPs) about Lilly's new rapid-acting mealtime insulin Lyumjev™ (insulin lispro-aabc injection, 100...

Lilly and Dexcom team up on new program to help improve diabetes management

An analyst's downgrade is weighing on the medical device stock.

Why DexCom Stock Is Slipping Today

SAN DIEGO--(BUSINESS WIRE)--Dexcom Schedules Third Quarter 2020 Earnings Release and Conference Call for October 27, 2020 at 4:30 p.m. Eastern Time

Dexcom Schedules Third Quarter 2020 Earnings Release and Conference Call for October 27, 2020 at 4:30 p.m. Eastern Time.

The partners will research the use of automated insulin delivery systems beyond the Type 1 diabetes market.

News for DexCom Stock (DXCM)